Announced details
Gout and hyperuricemia; pediatric hyperuricemia
The manufacturing and marketing approval for ユリス Tablets, originated by 株式会社富士薬品, changed from 株式会社富士薬品 to Mochida Pharmaceutical Co., Ltd. on 30 June 2026.
The company that originated ユリス Tablets. Other information, including its location, representative, business activities, capital, and year of establishment, is Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | ユリス Tablets (generic name: dotinurad; development code: FYU-981) |
| Counterparty | Fuji Yakuhin Co., Ltd. |
| Counterparty overview | The company that originated ユリス Tablets. Other information, including its location, representative, business activities, capital, and year of establishment, is Not disclosed. |
| Relationship with the Company | The manufacturing and marketing approval for ユリス Tablets, originated by 株式会社富士薬品, changed from 株式会社富士薬品 to Mochida Pharmaceutical Co., Ltd. on 30 June 2026. |
| Launch date | Launched in May 2020 (actual results) |
| Applicable area | Gout and hyperuricemia; pediatric hyperuricemia |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Hyperuricemia in children is often associated with an underlying disease, and drug treatment may be considered when the condition does not improve with lifestyle guidance or when the effects of such guidance are insufficient. Mochida Pharmaceutical aims to obtain approval so that it can contribute to improving the quality of life of pediatric patients.